A detailed history of Wasatch Advisors Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 23,346,013 shares of ESPR stock, worth $56.3 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
23,346,013
Previous 16,862,943 38.45%
Holding current value
$56.3 Million
Previous $37.4 Million 2.9%
% of portfolio
0.19%
Previous 0.2%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.61 - $2.73 $10.4 Million - $17.7 Million
6,483,070 Added 38.45%
23,346,013 $38.5 Million
Q2 2024

Aug 14, 2024

BUY
$1.84 - $3.24 $14.2 Million - $25.1 Million
7,733,296 Added 84.71%
16,862,943 $37.4 Million
Q1 2024

Apr 18, 2024

BUY
$2.02 - $3.02 $481,858 - $720,402
238,544 Added 2.68%
9,129,647 $24.5 Million
Q4 2023

Feb 14, 2024

SELL
$0.73 - $3.08 $1.92 Million - $8.12 Million
-2,634,997 Reduced 22.86%
8,891,103 $26.6 Million
Q3 2023

Nov 14, 2023

SELL
$0.96 - $1.79 $1.55 Million - $2.89 Million
-1,613,456 Reduced 12.28%
11,526,100 $11.3 Million
Q2 2023

Aug 07, 2023

SELL
$1.2 - $1.76 $257,556 - $377,748
-214,630 Reduced 1.61%
13,139,556 $18.3 Million
Q1 2023

May 12, 2023

BUY
$1.46 - $7.3 $9.5 Million - $47.5 Million
6,505,808 Added 95.0%
13,354,186 $21.2 Million
Q4 2022

Feb 14, 2023

SELL
$5.09 - $8.5 $3.13 Million - $5.22 Million
-614,638 Reduced 8.24%
6,848,378 $42.7 Million
Q3 2022

Nov 14, 2022

SELL
$5.45 - $8.13 $452,306 - $674,724
-82,992 Reduced 1.1%
7,463,016 $50 Million
Q2 2022

Aug 12, 2022

SELL
$4.77 - $6.67 $2.87 Million - $4.01 Million
-601,372 Reduced 7.38%
7,546,008 $48 Million
Q1 2022

May 13, 2022

BUY
$3.34 - $5.56 $5.88 Million - $9.79 Million
1,761,117 Added 27.58%
8,147,380 $37.8 Million
Q4 2021

Feb 15, 2022

BUY
$4.81 - $11.92 $15 Million - $37.1 Million
3,111,903 Added 95.04%
6,386,263 $31.9 Million
Q3 2021

Nov 12, 2021

SELL
$11.34 - $21.37 $5.59 Million - $10.5 Million
-492,575 Reduced 13.08%
3,274,360 $39.5 Million
Q2 2021

Aug 12, 2021

SELL
$19.4 - $28.71 $6.81 Million - $10.1 Million
-351,150 Reduced 8.53%
3,766,935 $79.7 Million
Q1 2021

May 10, 2021

BUY
$25.12 - $36.89 $3.02 Million - $4.43 Million
120,075 Added 3.0%
4,118,085 $116 Million
Q4 2020

Feb 12, 2021

BUY
$24.2 - $35.76 $38.4 Million - $56.8 Million
1,588,327 Added 65.91%
3,998,010 $104 Million
Q3 2020

Nov 10, 2020

BUY
$31.18 - $52.71 $36.3 Million - $61.4 Million
1,165,257 Added 93.64%
2,409,683 $89.6 Million
Q2 2020

Aug 12, 2020

BUY
$30.04 - $51.31 $10.2 Million - $17.3 Million
338,090 Added 37.3%
1,244,426 $63.9 Million
Q1 2020

May 08, 2020

BUY
$27.44 - $73.84 $6.63 Million - $17.8 Million
241,629 Added 36.35%
906,336 $28.6 Million
Q4 2019

Feb 13, 2020

BUY
$35.4 - $59.82 $1.21 Million - $2.05 Million
34,310 Added 5.44%
664,707 $39.6 Million
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $275,001 - $379,194
-7,978 Reduced 1.25%
630,397 $23.1 Million
Q2 2019

Aug 07, 2019

BUY
$40.1 - $52.33 $23,498 - $30,665
586 Added 0.09%
638,375 $0
Q1 2019

May 08, 2019

BUY
$40.11 - $53.57 $3.01 Million - $4.03 Million
75,165 Added 13.36%
637,789 $0
Q4 2018

Feb 14, 2019

BUY
$36.99 - $59.11 $197,489 - $315,588
5,339 Added 0.96%
562,624 $25.9 Million
Q3 2018

Nov 07, 2018

BUY
$40.74 - $51.41 $662,962 - $836,594
16,273 Added 3.01%
557,285 $0
Q2 2018

Aug 02, 2018

SELL
$36.2 - $76.4 $1.82 Million - $3.84 Million
-50,230 Reduced 8.5%
541,012 $0
Q1 2018

May 02, 2018

SELL
$65.94 - $80.76 $6.73 Million - $8.24 Million
-102,023 Reduced 14.72%
591,242 $0
Q4 2017

Jan 16, 2018

SELL
$43.47 - $67.43 $875,442 - $1.36 Million
-20,139 Reduced 2.82%
693,265 $0
Q3 2017

Nov 08, 2017

SELL
$43.8 - $52.77 $1.85 Million - $2.23 Million
-42,311 Reduced 5.6%
713,404 $0
Q2 2017

Aug 16, 2017

BUY
N/A
755,715
755,715 $0

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $160M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Wasatch Advisors Inc Portfolio

Follow Wasatch Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wasatch Advisors Inc with notifications on news.